Clinical Trials List
2024-01-01 - 2026-12-31
Phase III
Recruiting7
ICD-10D05.00
Lobular carcinoma in situ of unspecified breast
ICD-10D05.01
Lobular carcinoma in situ of right breast
ICD-10D05.02
Lobular carcinoma in situ of left breast
ICD-10D05.10
Intraductal carcinoma in situ of unspecified breast
ICD-10D05.11
Intraductal carcinoma in situ of right breast
ICD-10D05.12
Intraductal carcinoma in situ of left breast
ICD-10D05.80
Other specified type of carcinoma in situ of unspecified breast
ICD-10D05.81
Other specified type of carcinoma in situ of right breast
ICD-10D05.82
Other specified type of carcinoma in situ of left breast
ICD-10D05.90
Unspecified type of carcinoma in situ of unspecified breast
ICD-10D05.91
Unspecified type of carcinoma in situ of right breast
ICD-10D05.92
Unspecified type of carcinoma in situ of left breast
ICD-9233.0
Carcinoma in situ of breast
-
Trial Applicant
MEDPACE TAIWAN LIMITED
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/04/01
Investigators and Locations
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 沈士哲 無
- 張潤忠 無
- Pei-Wei Huang 無
- 何蕙余 無
- Yung-Chang Lin 無
- Chi-Chang Yu 無
- Wen-Chi Shen 無
- Wen-Ling Kuo 無
- Chan-Keng Yang 無
- 周旭桓 無
- Mengting Peng 無
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 巫承哲 無
- 高理鈞 無
- 甘蓉瑜 無
- 高捷妮 無
- Junping Shiau Shiau 無
- Chung-Liang Li 無
- Chieh-Han Chuang 無
- Shen Liang Shih 無
- Fang-Ming Chen 無
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- Yao-Lung Kuo 無
- Kuo-Ting Lee 無
- Zhu-Jun Loh 無
- 楊舜如 無
- Chun-Hui Lee 無
- Jui-Hung Tsai 無
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 陳怡君 無
- YEN-SHEN LU 無
- 林柏翰 Division of General Internal Medicine
- 張端瑩 無
- 蔡立威 無
- MING-YANG WANG 無
- Wei-Wu Chen 無
- 羅喬 無
- 林季宏 無
- 黃柏翔 無
The Actual Total Number of Participants Enrolled
0 Recruiting
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
21 participants
-
Global
500 participants
